Los Angeles Capital Management LLC Esperion Therapeutics, Inc. Transaction History

Los Angeles Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$19.4 - $28.71 $349,297 - $516,923	-18,005 Closed	0 $0
Q1 2021 May 05, 2021	SELL	$25.12 - $36.89 $328,117 - $481,857	-13,062 Reduced 42.04%	18,005 $505,000
Q4 2020 Feb 04, 2021	SELL	$24.2 - $35.76 $605 - $894	-25 Reduced 0.08%	31,067 $808,000
Q2 2020 Aug 05, 2020	SELL	$30.04 - $51.31 $6,759 - $11,544	-225 Reduced 0.72%	31,092 $1.6 Million
Q1 2020 May 04, 2020	SELL	$27.44 - $73.84 $248,825 - $669,581	-9,068 Reduced 22.45%	31,317 $987,000
Q4 2019 Feb 07, 2020	SELL	$35.4 - $59.82 $223,197 - $377,165	-6,305 Reduced 13.5%	40,385 $2.41 Million
Q3 2019 Nov 07, 2019	BUY	$34.47 - $47.53 $660,789 - $911,150	19,170 Added 69.66%	46,690 $1.71 Million
Q2 2019 Jul 29, 2019	BUY	$40.1 - $52.33 $1.1 Million - $1.44 Million	27,520 New	27,520 $1.28 Million
Q2 2018 Jul 31, 2018	SELL	$36.2 - $76.4 $114,392 - $241,424	-3,160 Closed	0 $0
Q1 2018 Apr 27, 2018	BUY	$65.94 - $80.76 $208,370 - $255,201	3,160 New	3,160 $229,000

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.